Biotech Seen Grinding Higher, Says RBC Capital (IBB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - Leerink
April 5, 2016 9:33 AM EDTLeerink affirms Intercept Pharma (Nasdaq: ICPT) at Market Perform with a price target of $144 as OCA briefing docs were posted ahead of an FDA panel this week.
ANalyst Joseph Schwartz commented, the FDA briefing documents for obeticholic acid (OCA) were released this morning and are largely in line with our recently-outlined expectations (LINK) and we maintain our opinion that ICPT is likely to receive a positive panel vote on Thursday, 4/7, and secure approval in the primary biliary cholangitis (PBC) indication by... More
